Steineger J, et al. - The researchers sought to assess in hereditary hemorrhagic telangiectasia (HHT), long-term follow-up of intranasal bevacizumab therapy. For most of the moderate and severe grades of HHT-associated epistaxis, intranasal bevacizumab injection was noted to be an effective treatment. In this trial, a variable duration of effect of the treatment was seen. Results demonstrated that the primary and late resistance phenomena to the intranasal bevacizumab therapy were quite common.